Cancer Research

Is TBC1D9B the Master Switch for Cellular Metabolism?
Research & Development Is TBC1D9B the Master Switch for Cellular Metabolism?

The human cell operates as a high-speed logistics hub where the physical location of cargo determines the fate of the entire biological operation. For decades, biology textbooks have described lysosomes as simple waste disposal units—tiny acidic balloons drifting through the cytoplasm to dissolve

How Does Biological Sex Affect Cancer Treatment Outcomes?
Research & Development How Does Biological Sex Affect Cancer Treatment Outcomes?

Groundbreaking research involving more than twenty thousand oncology patients has finally pulled back the curtain on a quiet crisis where medical treatments are inadvertently failing to account for the fundamental biological differences between men and women. For decades, the medical community

FDA Grants Orphan Drug Status to New Rare Blood Cancer Treatment
Biotech & Bioprocessing FDA Grants Orphan Drug Status to New Rare Blood Cancer Treatment

The landscape of hematologic oncology has long been a battlefield where patients and physicians fight a grueling war of attrition against diseases that are managed but rarely defeated. For those living with rare myeloproliferative neoplasms, the medical journey often feels like a series of

Scientists Map the Origins of Rare Pediatric Liver Cancer
Research & Development Scientists Map the Origins of Rare Pediatric Liver Cancer

Pediatric liver cancer research has entered a transformative era with the identification of Hepatoblastoma with carcinoma features (HBC), a complex third category that bridges the gap between traditional hepatoblastoma and hepatocellular carcinoma. Ivan Kairatov, a biopharma expert with extensive

Metabolic Enzyme PFK Found to Drive Cell Division via RNA
Research & Development Metabolic Enzyme PFK Found to Drive Cell Division via RNA

The boundaries between how a cell generates energy and how it decides to multiply have long been viewed as separate chapters in the book of biology, yet recent evidence suggests these processes are inextricably linked by a single, versatile protein. For over seventy years, scientists categorized

Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%
Research & Development Pfizer’s Next-Gen Cancer Drug Cuts Progression Risk by 40%

The current oncology landscape is defined by an urgent need for therapies that can bypass resistance mechanisms in advanced breast cancer while maintaining patient quality of life. Pfizer’s latest clinical data for atirmociclib suggests a significant advancement in achieving this balance through a

Loading

Subscribe to our weekly news digest.

Join now and become a part of our fast-growing community.

Invalid Email Address
Thanks for Subscribing!
We'll be sending you our best soon!
Something went wrong, please try again later